Catalys Pacific

Catalys Pacific is an independent venture capital firm founded in 2019, focused on early-stage life sciences. The firm operates from Japan and the United States, and describes its strategy as transpacific: combining local presence in both markets with a network spanning global academic institutions, biotechnology companies, venture firms and pharmaceutical groups. Its stated objectives are to advance healthcare innovation for unmet medical needs while generating risk-adjusted returns for investors.

The firm works along two lines. First, it makes early-stage life sciences investments through transpacific partnerships. Second, it founds and builds global bioventure companies - a company-creation model in which the firm assembles ventures around specific therapeutic programmes rather than backing existing teams alone. Among companies it has created are unnamed ventures developing therapies for hypertension and for kidney disease. Technical domains of interest include biotechnology, pharmaceutical research and development, drug development and healthcare innovation.

Operationally, Catalys Pacific works with research and development experts, advisers, local sourcing partners, institutions and syndicate co-investors, reflecting a collaborative approach to sourcing and building. The team is described as global, with experience across life sciences investing, R&D and entrepreneurship. The firm's stated mission is to improve patient lives worldwide by advancing therapeutic innovation where medical needs are unmet.